Miklos Egyed

9PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 01, 2026
High Prevalence of the JAK2V617F Mutation in Patients With Acute Coronary Syndrome.

|Jul 16, 2026
First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.

|Apr 08, 2025
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak

|Apr 21, 2024
Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.

Egyed Miklos, Tóth Peter Oliver, Kellner Adam

|Feb 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Stephen T Oh, Srdan Verstovsek, Vikas Gupta

|Oct 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.

Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano

Pageof 2

Frequent Collaborators

2 joint publications

Viktoria Gyorine Korom

2 joint publications

Wojciech Jurczak

1 joint publications

Rajnics Peter

1 joint publications

Vorobcsuk Andras